CRISPR Therapies, Base Editing and Approvals — 2026-09-27
This week's dominant story is Anthropic's announcement that its AI model Claude "autonomously discovered" a CRISPR-like enzyme system, sending gene-editing stocks sharply lower. Separately, Prime Medicine won FDA clearance for its first in vivo prime-editing clinical study in the U.S., while Beam Therapeutics advances BEAM-302 in AATD toward potential accelerated approval.
CRISPR Therapies, Base Editing and Approvals — 2026-09-27
Top developments
Anthropic's Claude "discovers" CRISPR-like system, hammering gene-editing stocks
On Wednesday (Sept. 23), Anthropic announced that its AI model Claude identified an undescribed enzyme system — dubbed ART — in phage DNA, featuring repeat arrays reminiscent of CRISPR, from its newly built in-house biology lab; data was released as a non-peer-reviewed preprint. Gene-editing equities fell: Prime Medicine dropped 11.58% and Editas 8% in a single session, amid what Chinese financial media described as "AI-replacement anxiety". Al Jazeera framed the announcement amid global debate over how to safeguard against catastrophic risks from AI-driven discovery. Seeking Alpha argued CRISPR Therapeutics remains a long-term buy anchored by Casgevy's success despite the AI-driven selloff.
FDA clears Prime Medicine's PM647, first U.S. in vivo prime-editing study
Prime Medicine received FDA clearance to advance PM647, an investigational in vivo Prime Editor for Alpha-1 Antitrypsin Deficiency (AATD), into U.S. clinical studies. The PiZZ genotype PM647 aims to correct affects roughly 100,000 people in the U.S. and an estimated 200,000 across the U.S. and Europe. In the same indication, Beam Therapeutics reported positive Phase 1/2 data for BEAM-302 and is targeting accelerated FDA approval with a 60 mg dose — a key competitive benchmark for both base and prime editing.
CRISPR Therapeutics: sideways stock, bullish calls after Anthropic shock
A 24/7 Wall St. analysis (Sept. 23) noted CRISPR Therapeutics has traded sideways and down for 12 months despite owning the only approved CRISPR medicine, with one analyst expecting up to 85% gains. The Motley Fool's Sept. 25 comparison piece contrasts CRISPR's cash-burning pipeline with Vertex's billions from a single therapy, underscoring divergent risk-reward profiles.
Local view
Chinese-language financial media (21经济网, via their Sept. 24 report citing 智通财经/SinoUs Financial) focused on the "AI substitution anxiety" theme, detailing single-day stock declines of 11.58% for Prime Medicine, 8% for Editas, and drops for Beam following Anthropic's announcement. ChainCatcher (Chinese crypto/AI news outlet) highlighted that the discovery came from Anthropic's new biology lab, staffed this past spring, and that data is preprint-only.
Context & numbers
- Casgevy lists at $2.2 million (versus $3.1 million for Lyfgenia), and Medicaid covers two-thirds of U.S. sickle cell patients — pricing and access remain the gating factors for uptake.
- CMS's Cell and Gene Therapy Access Model is now the main payer route: as of March 2026, 33 states and DC had signed on, allowing state Medicaid programs to negotiate outcomes-based contracts with Vertex and Bluebird with refunds if clinical benchmarks aren't met.
- FDA's draft guidance on genome-editing safety standards (April 2026) and its August 26, 2026 guidance on leveraging prior knowledge for rare-disease gene therapies (docket FDA-2026-D-1257) are shaping how in vivo editing products like PM647 must justify development pathways.
On the radar
- Beam Therapeutics' push for accelerated FDA approval of BEAM-302 for AATD at the 60 mg dose — a potential first commercial base-editing approval pathway to watch.
- Whether or not ART, the Claude-discovered CRISPR-like system, proves functional — currently unverified preprint data; if confirmed, it could seed a new editing mechanism.
- The FDA's docket for comment on genome-editing prior-knowledge guidance (FDA-2026-D-1257) — comment-period activity could influence timing for in vivo editing sponsors.
- Rumor/rumor-adjacent: continued analyst speculation on CRSP share recovery (an 85% upside call) is opinion, not company guidance — treat with caution.
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
